FDA Drug Safety Communication: Updated Risk Evaluation and Mitigation Strategy (REMS) to Restrict Access to Rosiglitazone-containing Medicines including Avandia, Avandamet, and Avandaryl
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere que se eliminen ciertas restricciones al recetar y dispensar medicamentos para la diabetes que contienen rosiglitazona
El 25 de noviembre, 2013, La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) ha determinado que datos recientes sobre medicamentos que contienen rosiglitazona, como Avandia, Avandamet, Avandaryl y versiones genéricas, no indican un riesgo mayor de ataque al corazón en comparación con los med icamentos estándar metformina y sulfonilurea para la diabetes de tipo 2. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 5, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Yale study adds to evidence of diabetes drug link to heart problems
(Yale School of Public Health) A new study published by The BMJ adds to evidence that rosiglitazone -- a drug used to treat type 2 diabetes -- is associated with increased risk of heart problems, especially heart failure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 11, 2020 Category: International Medicine & Public Health Source Type: news

Diabetes drug may increase risk of cardiovascular complications
According to a study published inThe BMJ, Rosiglitazone, a drug used to treat type 2 diabetes, may increase the risk of cardiovascular complications.Medical News Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 7, 2020 Category: Endocrinology Source Type: news

Meta-Analyses Link Rosiglitazone to Increased Cardiovascular Risk
THURSDAY, Feb. 6, 2020 -- Rosiglitazone seems to be associated with an increased cardiovascular risk, particularly heart failure, according to data from a systematic review and meta-analyses published online Feb. 5 in The BMJ. Joshua D. Wallach,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2020 Category: Pharmaceuticals Source Type: news

Largest ever evaluation of the cardiovascular risk of rosiglitazone published
Analysis of raw individual patient level data gives more accurate picture of drug ’s link to heart problems Related items fromOnMedica People on statins at greater risk of skin infections and diabetes Adding insulin to metformin linked to higher mortality Vitamin D does not reduce kidney damage in type 2 diabetes Raised risk of MI and mortality when starting sulfonylurea Use of DPP-4 inhibitors associated with increased risk of IBD (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 5, 2020 Category: UK Health Source Type: news

rosiglitazone (Avandia)
Title: rosiglitazone (Avandia)Category: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 11/15/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 15, 2019 Category: Endocrinology Source Type: news

People on statins at greater risk of skin infections and diabetes
Monitor blood glucose levels of patients predisposed to diabetes, and be mindful of possible raised SSTI risks Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD UK research reveals racial inequalities in diabetes care Regulators suspend Avandia over safety concerns Daily aspirin use linked to major bleeding Statins linked to raised diabetes risk, study suggests (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 9, 2019 Category: UK Health Source Type: news

Polycystic Ovary Syndrome Awareness Month
September is   Polycystic Ovary Syndrome Awareness Month and is an excellent time to focus on the latest Cochrane evidence.Polycystic ovary syndrome (PCOS) is a very common condition affecting 8% to 13% of women. Being overweight worsens all clinical features of PCOS. These clinical features include reproductive issues such as reduced frequency of ovulation and irregular menstrual cycles, reduced fertility, polycystic ovaries onultrasound and high levels of male hormones such as testosterone, which can cause unwanted facial or body hair growth and acne. PCOS is also associated with metabolic features, withrisk factors for...
Source: Cochrane News and Events - September 3, 2019 Category: Information Technology Authors: Muriah Umoquit Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: FDA eliminates the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing diabetes medicines
[12-16-2015] The U.S. Food and Drug Administration (FDA) is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 18, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Diabetes drug may help to treat breast cancer
Research, published inCancer Cell, suggests that the diabetes drug rosiglitazone, combined with trametinib, could treat breast cancer by turning cancerous cells into fat cells. Science Alert (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 15, 2019 Category: Endocrinology Source Type: news

Genetics may predict diabetes drug side-effects
Research, published inCell Stem Cell, suggests that genetic variations in a patient’s fat cells can determine if the diabetes drug, rosiglitazone, will have unwanted side-effects. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 11, 2019 Category: Endocrinology Source Type: news

Early age type 1 diabetes linked to shorter life expectancy than later age diagnosis
Consider earlier and wider use of preventive treatment, researchers urge Related items fromOnMedica Too few women take part in many CVD clinical trials Children risking heart health through unhealthy lifestyles Hereditary heart and diabetes problems raise risk for children Regulators suspend Avandia over safety concerns Fat children have high cardiovascular risks as teens (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 10, 2018 Category: UK Health Source Type: news